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S100A2 is a BRCA1/p63 coregulated tumour
suppressor gene with roles in the regulation of mutant
p53 stability
NE Buckley*,1, Z D’Costa1, M Kaminska1 and PB Mullan1
Here, we show for the first time that the familial breast/ovarian cancer susceptibility gene, BRCA1, along with interacting DNp63
proteins, transcriptionally upregulate the putative tumour suppressor protein, S100A2. Both BRCA1 and DNp63 proteins are
required for S100A2 expression. BRCA1 requires DNp63 proteins for recruitment to the S100A2 proximal promoter region, while
exogenous expression of individual DNp63 proteins cannot activate S100A2 transcription in the absence of a functional BRCA1.
Consequently, mutation of the DNp63/p53 response element within the S100A2 promoter completely abrogates the ability of
BRCA1 to upregulate S100A2. S100A2 shows growth control features in a range of cell models. Transient or stable exogenous
S100A2 expression inhibits the growth of BRCA1 mutant and basal-like breast cancer cell lines, while short interfering RNA
(siRNA) knockdown of S100A2 in non-tumorigenic cells results in enhanced proliferation. S100A2 modulates binding of mutant
p53 to HSP90, which is required for efficient folding of mutant p53 proteins, by competing for binding to HSP70/HSP90 organising
protein (HOP). HOP is a cochaperone that is required for the efficient transfer of proteins from HSP70 to HSP90. Loss of S100A2
leads to an HSP90-dependent stabilisation of mutant p53 with a concomitant loss of p63. Accordingly, S100A2-deficient cells are
more sensitive to the HSP-90 inhibitor, 17-N-allylamino-17-demethoxygeldanamycin, potentially representing a novel therapeutic
strategy for S100A2- and BRCA1-deficient cancers. Taken together, these data demonstrate the importance of S100A2
downstream of the BRCA1/DNp63 signalling axis in modulating transcriptional responses and enforcing growth control
mechanisms through destabilisation of mutant p53.
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BRCA1 was initially cloned in 1994 as one of the genes
predisposing to early-onset breast and ovarian cancer.1
BRCA1 germline mutations confer a cumulative lifetime risk
of 50–85 and 12–60% of developing breast and ovarian
cancer, respectively.2 Somatic BRCA1 mutations are rare in
sporadic breast cancer, but BRCA1 expression is down-
regulated in B30% of sporadic cases.3 BRCA1 is known to
have multiple roles including DNA damage repair, cell cycle
checkpoint control and transcriptional regulation. Although
BRCA1 does not bind to DNA in a sequence-specific manner,
it facilitates transcriptional control at a number of different
levels (e.g. interacts with transcription factors, the RNA
polymerase II holoenzyme complex and proteins involved in
chromatin remodelling; for a review see Mullan et al.4).
Through these multiple interactions, BRCA1 can coactivate or
corepress a large number of target genes involved in its
downstream functions.
Our group has recently identified the DNp63 family of
proteins as novel BRCA1 interactors with important roles in
BRCA1-mediated tumour suppression.5 Our data suggest
that the transcriptional control of DNp63 expression by
BRCA1 is important for the maintenance of genomic stability
and for the normal differentiation of mammary tissue. The
tumour suppressor role of p63 in breast tissue was also
demonstrated by the finding that mutant p53 proteins may
drive tumourigenesis through the formation of p53–SMAD
complexes, which interacts with and opposes p63 function,
leading to enhanced metastasis.6
The family of S100 proteins is a highly conserved group of
more than 20 members of small (9–13 kDa) acidic calcium-
binding proteins.7 Numerous S100 proteins are known to be
overexpressed in cancers, while S100A2 is thought to
primarily act in a tumour-suppressive role.8–10 S100A2
expression is downregulated in several tumour types includ-
ing breast cancer,11 with promoter methylation being one
mechanism responsible for this.9 A number of S100 proteins
have been shown to interact with the p53 tumour suppressor,
interactions that may be influenced through p53 phosphoryla-
tion and acetylation events, potentially activating as well as
inhibiting p53.12 Specifically, S100A2 is known to interact with
wild-type p53 and other p53 family members to enhance their
transcriptional activity.13 S100A2 has been shown previously
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to be a direct transcriptional target of both p63 and p73
proteins.14,15 The function of S100A2 (also called S100L) is
still unknown but it is localised to the basal layer of normal
human epidermis and hair follicles, possibly reflecting its p63-
dependent activation.16,17
In this study, we show that S100A2 is a coregulated target
of both BRCA1 and DNp63, requiring both proteins to be
expressed and fully functional for optimal S100A2 expression.
We observe consistent growth inhibitory effects in multiple
breast cancer cell lines and non-tumourigenic breast cell lines,
consistent with its role as a tumour suppressor in breast
tissue. S100A2 knockdown results in an increase in mutant
p53 with a concomitant loss of p63. We demonstrate that the
observed increase in p53 is owing to HSP90-dependent
stabilisation and S100A2-depleted cells are therefore more
sensitive to the HSP90 inhibitor, 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG). Taken together, these
data suggest a role for a BRCA1-DNp63-S100A2 signalling
pathway important for the growth control of breast tissue
through the regulation of HSP90–client protein interaction.
Results
We have consistently observed S100A2 as a positively
regulated BRCA1 target gene following several microarray
experiments (data not shown). To validate this, we first stably
reconstituted wild-type BRCA1 into the BRCA1 mutant
HCC1937 and basal-like (BRCA1 low-expressing) MDA-MB-
468 cells. Figure 1ai shows western blot analyses of
HCC1937-BR cells showing marked upregulation of S100A2
protein following BRCA1 reconstitution relative to the empty
vector (EV) control cell line, HCC1937-EV. Figure 1aii
confirmed that this effect was transcriptional with an appro-
ximate fivefold upregulation of S100A2 mRNA. Similar effects
were observed with MDA-MB-468 cells relative to EV controls
(Figures 1bi and ii). In contrast, siRNA knockdown of BRCA1
in non-tumourigenic HME-1 (Figures 1ci and ii) or luminal
MCF7 cells (Figures 1di and ii) resulted in respective
downregulation of S100A2 proteins and mRNAs. S100A2
was also shown to be downregulated in BRCA1-associated
tumours using publically available data sets (Supplementary
Figure 1). Clearly, S100A2 is regulated by BRCA1 at a protein
and mRNA level in multiple breast cell lines and in primary
breast cancers.
As detailed in the Introduction, we recently identified the
DNp63 family of proteins as BRCA1 transcriptional targets.5
BRCA1 transcriptionally regulates these proteins through
specific interaction with DNp63g to drive a positive DNp63
regulatory loop. S100A2 has already been described as a p63
target gene,14,15 so we decided to investigate the mechanism
underpinning S100A2 upregulation. Both HCC1937- and
MDA-MB-468 BRCA1-reconstituted cell lines were treated
(alongside EV controls) with DNp63siRNA. As Figures 2a and b
show, we observed strong induction of DNp63 in BRCA1-
reconstituted cells (relative to EV controls) accompanied by
pronounced upregulation of S100A2. However, DNp63 siRNA
totally abrogated S100A2 protein and mRNA in BRCA1-
reconstituted cells, showing that the BRCA1–DNp63 complex
is a crucial regulator of S100A2. To demonstrate the DNp63
specificity, we performed DNp63-, TAp63- and p53-specific
siRNA knockdowns in MCF7 cells (Supplementary Figure 2A)
and immunoblotted for S100A2. As Figure 2ci shows, only
DNp63 knockdown reduced S100A2 levels and this was
consistent for g- or a/b-specific siRNAs (Figure 2cii, knock-
downs shown in Supplementary Figure 2Bi). Similar results
are also seen with knockdown of mutant p53 in the MDA-BR
Figure 1 Western blot analysis of (ai) BRCA1 mutant HCC1937 and (bi)
BRCA1 low MDA468 (MDA-MB-468) breast cancer cells, stably transfected with EV
or wild-type BRCA1 (BR). Blots were probed with BRCA1, S100A2 and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a loading control.
Real-time polymerase chain reaction (PCR) analysis of (aii) HCC EV and BR and
(bii)) MDA468 EV and BR cells with primers specific for S100A2. GAPDH was used
as a housekeeper. Western blot analysis of (ci) HME1 and (di) MCF7 breast cancer
cells transiently transfected with siRNA targeting BRCA1 (BRsi) or scrambled
control (Scr). Blots were probed with BRCA1, S100A2 and GAPDH as a loading
control. (cii and dii) Real-time PCR analysis of the same samples as before with
primers specific for S100A2. GAPDH was used as a loading control
BRCA1 and p63 coregulate S100A2 to modulate mutant p53 stability
NE Buckley et al
2
Cell Death and Disease
cell lines (Supplementary Figure 2C). p63 often transcription-
ally activates basal target genes in collaboration with the AP2
family of proteins.18 We were able to show that AP2a was also
required for S100A2 activation (Figure 2cii, knockdowns
shown in Supplementary Figures 2Bii and iii). Finally, we
decided to investigate if exogenous expression of p63 could
bypass the requirement for BRCA1 expression and activate
S100A2 independently. BRCA1 mutant HCC1937 cells were
transfected with either an EV construct or different DN- or TA-
p63 isoforms. As Figure 2d shows, only BRCA1 reconstitution
restored S100A2 expression, suggesting that for S100A2
promoter activation, BRCA1 was still required regardless of
p63 levels. These data together show that both BRCA1 and
DNp63 proteins (in collaboration with AP2a) are required for
optimal activation of S100A2 transcription.
Next, we wanted to define exactly how BRCA1 modulated
S100A2 promoter activity. We PCR cloned the proximal
S100A2 promoter and transfected into a variety of cell lines
with modulated BRCA1. For both HCC1937- and MDA-MB-
468 BRCA1-reconstituted cells, we observed significant
Figure 2 (ai) Western blot analysis of BRCA1 mutant HCC 1937 cells stably transfected with either EV or wild-type BRCA1 (BR) and transiently transfected with siRNA
targeting DNp63 (DNp63si) or scrambled control (Scr). Blots were probed with p63, S100A2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a loading control.
(aii) Real-time polymerase chain reaction (PCR) analysis of the same samples as (i) with specific primers for S100A2 and b-tubulin as a housekeeper. (bi) Western blot
analysis of BRCA1 low MDA468 cells stably transfected with either EV or wBR and transiently transfected with siRNA targeting DNp63 (DNp63si) or Scr. Blots were probed
with p63, S100A2 and GAPDH as a loading control. (bii) Real-time PCR analysis of the same samples as (i) with specific primers for S100A2 and b-tubulin as a housekeeper.
(ci) Western blot analysis of MCF-7 cells transiently transfected with siRNA targeting DNp63 (DNp63si), TAp63 (TAp63si), p53 (p53si) or Scr. Blots were probed with S100A2
and GAPDH as a loading control. (cii) Western blot analysis of MCF-7 cells transiently transfected with siRNA targeting p63g (p63gsi), p63a and b (p63a/b si), all p63 isoforms
(pan-p63), AP2a (AP2asi), AP2g (AP2gsi) and Scr. Blots were probed with S100A2 and GAPDH as a loading control. (d) Western blot analysis of HCC BR cells or HCC 1937
cells transiently transfected with EV, DNp63a, DNp63g, TAp63a or TAp63g. Blots were probed for S100A2, p63 and GAPDH as a loading control
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luciferase activities that were markedly reduced with siRNA
against DNp63 (Figures 3ai and ii). Similarly, BRCA1 and
DNp63 siRNA knockdowns in MCF7 cells reduced S100A2
luciferase, while p53 knockdown had minimal effect
(Figure 3aiii). In addition to the previously characterised p53
binding site located B2200 bp upstream of the untranslated
exon 1 of the S100A2 gene,19 Kirschner et al.15 described a
second p63-specific binding site located just upstream of the
first exon. While deletion of the p53-responsive site had no
effect on the observed luciferase activity, we could demon-
strate that the predicted DNp63 binding site was responsible
for this activation since site-directed mutagenesis of this site
completely abrogated the BRCA1-dependent luciferase acti-
vation in both HCC1937 and MDA-MB-468 cell models
(Figures 3bi and ii, respectively). We also PCR cloned two
regions within intron 2 of S100A2, which have been shown to
be p63 responsive.14 Although these regions were p63
responsive, they did not appear to be consistently regulated
by BRCA1 (Supplementary Figure 3); therefore, these
promoter regions were not studied further. Chromatin
immunoprecipitation (ChIP) assays showed localisation of
both BRCA1 and DNp63 to the S100A2 proximal promoter
region, while an upstream ( 2 kB) region showed no obvious
recruitment of either protein (Figure 3ci). Finally, we could
demonstrate the requirement for DNp63 for BRCA1 recruit-
ment to the S100A2 promoter usingDNp63 siRNA knockdown
followed by ChIP assay, showing total loss of BRCA1
recruitment following DNp63 siRNA (Figure 3cii). Taken
Figure 3 (a) Luciferase reporter assay of (i) HCC EV and wild-type BRCA1 (BR) cells and (ii) MDA EV and BR cells transiently transfected with siRNA targeting DNp63
(p63si) or scrambled control (Scr). Cells were then transfected with either S100A2 promoter construct (S100A2pro) or the EV control (pGL3). Renilla was used to normalise for
transfection efficiency. Values are expressed as relative luciferase units (RLUs) normalised to pGL3 and Renilla. (iii) Luciferase reporter assay of MCF7 cells transiently
transfected with siRNA targeting BRCA1 (BRsi),DNp63 (DNsi), p53 (p53si) or Scr. Cells were then transfected with either S100A2 promoter construct (S100A2pro) or the EV
control (pGL3). Renilla was used to normalise for transfection efficiency. Values are expressed as RLUs normalised to pGL3 and Renilla. (b) Luciferase reporter assay of (i)
HCC EV and BR cells and (ii) MDA EV and BR cells transfected with either an S100A2 promoter construct (S100A2pro), an S100A2 promoter construct with one p53/p63
binding site deleted (Del), an S100A2 promoter construct with one p53/p63 binding site deleted and the second mutated (SDM) or the EV control (pGL3). Renilla was used to
normalise for transfection efficiency. Values are expressed as RLUs normalised to pGL3 and Renilla. (ci) ChIP assay of MDA468 BR cells showing localisation of p63 and
BRCA1 on the S100A2 promoter. One per cent of sonicated lysate before immunoprecipitation was used as a positive control (input) and IgG pulldown was used as a negative
control (IgG1 and IgG2a). In addition, polymerase chain reaction (PCR) primers for a region upstream of the S100A2 promoter show specificity for the promoter. (ii) ChIP assay
of MDA468 BR cells transiently transfected with siRNA targeting DNp63 (DNp63si) or Scr showing recruitment of BRCA1 and p63 to the S100A2 promoter. One per cent of
sonicated lysate before immunoprecipitation was used as a positive control (input) and IgG pulldown was used as a negative control (IgG1 and IgG2a). In addition, PCR primers
for a region upstream of the S100A2 promoter shows specificity for the promoter
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together, these data demonstrate that DNp63-dependent
recruitment to a specific site in the S100A2 promoter is
required for its transcriptional activation.
S100A2 has previously been reported to act as a tumour
suppressor gene in breast tissue;10 thus, we wanted to
address the functional consequences of S100A2 loss and how
important this protein was for BRCA1-mediated tumour
suppression. Stable exogenous S100A2 expression was
performed in the BRCA1-defective HCC1937, MDA-MB-468
and transient S100A2 expression in the SUM149 cells
(Figures 4ai–ii and Supplementary Figure 4Aii) resulted in a
reproducible inhibition of cell growth, as assessed by 5-day
growth curves (Figures 4bi–ii and Supplementary Figure Ai).
Again knockdowns of S100A2 in BRCA1-proficient, non-
Figure 4 (a) Western blot analysis of (i) MDA468 or (ii) HCC1937 cells stably transfected with either EV or S100A2 or (iii) HME-1 cells transiently transfected with siRNA
targeting S100A2 or scrambled control (Scr) probed for S100A2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a loading control. (b) Five-day growth curve of
the same samples as (a). (c) Western blot analysis of (i) MDA BR or (ii) HCC BR cells transiently transfected with siRNA targeting S100A2 or Scr. Blots were probed for
S100A2, p53, p63 and b-tubulin as a loading control. Western blot analysis of (iii) MDA 468 and (iv) HCC 1937 cells stably transfected with either EV or S100A2. Blots were
probed for S100A2, p53, p63 and b-tubulin as a loading control. (d) Real-time polymerase chain reaction (PCR) analysis of (i) MDA BR or (ii) HCC BR cells transiently
transfected with two independent siRNAs targeting S100A2 (S100A2 no. 2 and S100A2 no. 3) and Scr using primers specific for S100A2, p53, p63 (pan), CyclinG2, Sharp1
and Caveolin1 (Cav1). Real-time PCR analysis of (iii) MDA 468 and (iv) HCC 1937 cells stably transfected with either EV or S100A2 using primers specific for S100A2, p53,
p63 (pan), CyclinG2, Sharp1 and Caveolin1 (Cav1)
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tumourigenic HME1 and MCF10-A cells (Figure 4aiii and
Supplementary Figure 4Bii) resulted in enhanced proliferation
(Figure 4biii and Supplementary Figure 4Bi). Consistent with
previous findings, the effect of S100A2 on cell numbers
appears to be through the regulation of transition from the S to
G2/M phase of the cell cycle and not through the regulation
of cell viability.20 Although PARP cleavage (indicative of
apoptosis) is not observed when S100A2 is modulated
(Supplementary Figure 4C), there is an increase in the
number of cells in the S phase (as measured by bromodeoxy-
uridine (BrdU) incorporation) when S100A2 is stably over-
expressed in HCC1937 and the opposite seen when S100A2
is depleted by siRNA (Supplementary Figure 4D). An
interesting observation was made that while BRCA1 and
DNp63 knockdowns resulted in S100A2 downregulation,
S100A2 siRNA also resulted in an increase in mutant p53
protein levels with a concomitant reduction in DNp63 protein
levels in both HCC1937-BR and MDA-MB-468-BR cell lines
(Figures 4ci–ii). Similar effects were also observed with
BRCA1 and DNp63siRNA (Supplementary Figure 5), as
well as in the BRCA1 low expression MDA468-EV cells
(Supplementary Figure 2C). Using the converse approach of
stable overexpression of S100A2 in the BRCA1-deficient
MDA-MB-468 and HCC1937 cells, we observed a decrease
in mutant p53 protein levels and an increase in DNp63 protein
levels (although DNp63 levels were considerably lower than
those observed in BRCA1-proficient cell lines) (Figures 4ciii
and iv). Although the effect on p53 levels was not transcrip-
tional, the effect on DNp63 was clearly evident at an mRNA
level (Supplementary Figure 5B). Previous studies have
demonstrated that mutant p53, particularly ‘gain-of-function’
mutant p53 proteins are able to interfere with the tumour-
suppressive role of p63 to drive metastasis.6 Accordingly, the
expression of p63 target genes, CyclinG2, Sharp1 and
Caveolin1, were all modulated in an S100A2-dependent
manner (Figure 4d). Studies are ongoing to determine the
exact mechanism of how S100A2 regulates p63; however,
preliminary results (Supplementary Figure 5C) indicate it may
be dependent on the ability of mutant p53 to oppose p63
function and this would impact on the autoregulation of p63
through the C40 enhancer region.5,21
As S100A2 levels appeared to antagonise mutant p53
expression, we hypothesised that S100A2 may somehow
alter the stability of mutant p53 to suppress tumourigenesis.
It has been documented that certain p53 missense mutants are
dependent on chaperones such as HSP90 for their stability.22
Given the ability of S100A2 to interact with the cochaperone
HSP70/HSP90 organising protein (HOP) and therefore
modulate the transfer of client proteins from HSP70 to
HSP90,23 we investigated the effect of S100A2 on the
chaperone-dependent folding and thus the stability of mutant
p53. Levels of mutant p53 in the denatured and native
conformation were quantified by immunoprecipitation using
specific antibodies (PAb-240 and PAb-1620, respectively)
and compared with total levels as determined by immunopre-
cipitation with an antibody that detects total p53 levels (DO-1).
Following knockdown of S100A2 in MDA468-BR cells, total
p53 increased as shown previously (Figure 5ai and
Supplementary Figure 6Ai). As the majority of the contact
mutant (R280H) p53 in the MDA-MB-468 cell line is found in
the native conformation,22 it was only possible to compare the
overall levels of mutant p53. Knockdown of S100A2 resulted
in an increase in the native form of mutant p53, normalised to
total p53 protein (Figure 5aii and Supplementary Figure 6Ai).
Conversely, stable overexpression of S100A2 in the
HCC1937 cells resulted in the expected decrease in total
p53 (Figure 5bi and Supplementary Figure 6Aii) with a
decrease in the native form and an increase in the denatured
form of mutant p53 (Figures 5bii and iii and Supplementary
Figure 6Aii). To determine if S100A2 modulated the binding of
mutant p53 to HSP90, we assessed the amount of denatured
mutant p53 interacting with HSP90 by immunoprecipitation.
In MDA468-BR cells, knockdown of S100A2 resulted in
an increase in denatured p53 interacting with HSP90
(Figure 5ci). Conversely, overexpression of S100A2 in the
HCC1937 cell led to a decrease (Figure 5cii). We confirmed
that S100A2 interacted with HOP (but not HSP90) by
immunoprecipitation (Figure 5di) and demonstrated that loss
of S100A2 expression results in increased HOP–HSP90
interaction (Figure 5dii) and therefore predicts for increased
client protein transfer from HSP70 to HSP90. Next, we utilised
the HSP-90 inhibitor, 17-AAG, to evaluate the dependency of
mutant p53 for HSP90-mediated folding. Knockdown of
S100A2 in MDA468-BR cells led to the expected increase in
mutant p53, but this was abrogated by treatment with 17-AAG
(Figure 5ei). These cells were also more sensitive to the
inhibitor (relative to scrambled control siRNA-treated cells)
(Figure 5fi and Supplementary Table 1). Similar results are
also seen in the HCCBR and HME-1 cells following siRNA
(Supplementary Figure 6B and Supplementary Table 1),
Figure 5 (a) Quantitation by densitometry of immunoprecipitation (IP) in MDA BR cells transiently transfected with two independent siRNAs targeting S100A2 (S100A2 no.
2 and S100A2 no. 3) and scrambled control (Scr). (i) Total p53 was immunoprecipitated using DO1 and (ii) folded/native conformation p53 was immunoprecipitated using
pAB1620. (b) Quantitation by densitometry of IP in HCC 1937 cells stably transfected with EV or S100A2. (i) Total p53 was immunoprecipitated using DO1, (ii) folded/native
conformation p53 was immunoprecipitated using pAB1620 and (iii) denatured p53 was immunoprecipitated using pAB240. (c) Co-immunoprecipitation of (i) MDA BR cells
transiently transfected with siRNA targeting S100A2 (SA2si) and Scr and (ii) HCC1937 cells stably transfected with EV or S100A2 (SA2). Cell lysates were immunoprecipitated
with pAB240, and then following western blot analysis, probed for HSP90. (di) IP-western blot analysis of MDA BR cells. Whole-cell lysate was immunoprecipitated with either
S100A2 antibody or an IgG control followed by western blot analysis. Blots were probed with HSP90, HOP or S100A2. (ii) IP-western blot of MDA BR cells was transiently
transfected with two independent siRNAs targeting S100A2 (S100A2 no. 2 and S100A2 no. 3) and Scr. Whole-cell lysate was immunoprecipitated with either HSP90 or IgG
control followed by western blot analysis. Blots were probed for HSP90, HOP and S100A2. (ei) Western blot analysis of MDABR cells transiently transfected with two
independent siRNAs targeting S100A2 (SA2si no. 2 and no. 3) or Scr. Cells were then treated with 4 mM 17-AAG or vehicle control for 16 h. Blots were probed with p53,
S100A2 or b-tubulin as a loading control. (ii) Western blot analysis of HCC1937 cells stably transfected with EV control or S100A2 (SA2). Cells were treated with 2 mM 17-AAG
or vehicle control for 16 h. Blots were probed with p53, S100A2 and b-tubulin as a loading control. (f) Dose–response curve of (i) MDA BR cells transiently transfected with two
independent siRNAs targeting S100A2 (S100A2 no. 2 and no. 3) and Scr and (ii) HCC1937 cells stably transfected with EV or S100A2 (S100A2). Cells were treated with the
indicated range of concentration of 17-AAG for 72 h before cell viability was assessed by MTT. Cell survival was normalised to vehicle control (100%)
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as well as in HCC1937 cells stably reconstituted with S100A2,
with S100A2 conferring over 10-fold decrease in sensitivity
to 17-AAG compared with EV control (Figures 5eii and fii
and Supplementary Table1). Using cell line data from
Lehmann et al.,24 IC50 values for the 17-AAG analogue,
17-dimethylaminoethylamino-17-demethoxygeldanamycin
BRCA1 and p63 coregulate S100A2 to modulate mutant p53 stability
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(17-DMAG), were extrapolated and correlation with S100A2
expression levels (as determined by microarray analysis of
the same publically available data sets utilised in the study)
was assessed (Supplementary Figure 6C and Supplementary
Table1). This showed highly significant correlation between
S100A2 levels and sensitivity to HSP90 inhibition. Taken
together, these data highlight the important role of S100A2 as
a regulator of mutant p53 protein levels and sensitivity to
HSP90 inhibition.
Discussion
In this study, we have identified S100A2 as an integral
component of BRCA1 tumour suppression downstream of the
BRCA1–DNp63 transcription complex. We show that S100A2
consistently represses cell proliferation in a range of breast
cell lines and that S100A2 expression is doubly important for
regulating both the optimal transcription of p63 and for helping
to destabilise mutant p53 protein levels. We have shown that
S100A2 interferes with the transfer of client proteins from
HSP70 to HSP90, therefore inhibiting the folding and
stabilisation of the mutant protein. Inhibition of HSP90
abrogates the increase in mutant p53 observed when
S100A2 expression is lost and S100A2-deficient cells are
acutely sensitive to the HSP90 inhibitor, 17-AAG.
The role of S100A2 in tumour suppression is still poorly
described. S100A2 is the only member of the S100 family that
appears to act in a tumour-suppressive manner, while the
others have oncogenic roles. Of interest, our colleagues have
previously identified a number of S100 family members as
genes repressed by BRCA1.25 The BRCA1-dependent repres-
sion of S100A7 (or psoriasin) was shown to have as pivotal role
in BRCA1-dependent resistance to the DNA-damaging agent,
etoposide.25 Our data show that S100A2 is an important
effector of the BRCA1/p63 tumour-suppressive pathway that
we have described previously.5 The observation that loss of
S100A2 leads to a downregulation of p63 means that any
mechanism leading to a loss of S100A2 expression, such as
promoter methylation, may result in a loss of the BRCA1/p63
tumour suppressor function leading to tumourigenesis.
Much of the interest into the role of S100A2 as a tumour
suppressor relates to its coactivation of wild-type p53 target
genes.13 However, this is the first time that S100A2 has been
shown to modulate mutant p53 protein stability. Up to 40% of
human cancers express high levels of mutant p53 and 74% of
these are missense mutations that fall within its central DNA-
binding domain.26 Using both zebrafish and mouse models,
studies have shown that mutation alone is not sufficient to
confer stability to the protein in the absence of stress.27,28
Therefore, tumour-specific activation of p53 stabilisation
pathways is required – an area that is still poorly understood.
Initially, it was thought that the increase in stability of mutant
p53 was owing to the fact that it did not induce the wild-type
p53 target gene, MDM2. However, this is an oversimplified
view as mice engineered to express mutant p53 only show
higher protein expression in tumour and not normal tissue.29
The role of molecular chaperones, such as HSP70 and
HSP90, has more recently come to light as an important
mechanism of regulation of mutant p53. When p53 binds to
HSP90, this inhibits its ability to interact with MDM2, thereby
inhibiting its ubiquitination and subsequent degradation.30–32
The importance of the interplay between the molecular
chaperones and additional ubiquitin ligases such as p300
and CHIP is also becoming more apparent.33,34 Alterations in
the balance of chaperone-dependent folding of the mutant
protein and proteasome-dependent degradation may con-
tribute to the tumour-specific stabilisation observed.22 Muller
et al.22 showed that HSP90 is required to fold mutants into the
native conformation or, alternatively, forms a stable complex
with mutants that adopt an unfolded conformation. This
protects them from binding to HSP70 and subsequent
CHIP-dependent degradation. HSP90 has been shown to
be highly active in tumours cells35 and the relative levels of
HSP90 and HSP70 may help to explain some of the
heterogeneous expression patterns of mutant p53.
A key step in the HSP90-dependent stabilisation of mutant
p53 is the transfer of the native or denatured p53 protein from
HSP70 to HSP90. This is facilitated by cochaperones
including HOP.36 HOP contains multiple tetratricopeptide
repeat (TPR) domains that allow it, and other proteins with this
motif, to interact with the C terminus of HSP90 and HSP70 to
facilitate client protein transfer. S100A2 has been shown to
bind to the TPR domain of HOP, resulting in the inhibition of
HOP–HSP70 and HOP–HSP90 interactions.37 This means
that S100A2 regulates the key step in stabilisation of mutant
p53 by modulating the transfer of the protein from HSP70 to
HSP90 and thus protecting it from HSP70/CHIP-dependent
degradation. Indeed, our results show S100A2 modulating the
levels of mutant protein bound to HSP90. More recently,
S100A2 has also been shown to regulate CHIP itself.38 This
study, however, implies that loss of S100A2 would lead to
increased degradation of mutant p53, which contradicts both
our findings and the role for S100A2 as a tumour suppressor.
We have shown that S100A2 has an important role in
regulating the proliferation of a range of breast cancer cell
lines through regulation of the mutant p53/p63 signalling axis,
which will further impact on the aggressiveness and meta-
static potential of tumours.6,39 However, the ability of S100A2
to regulate mutant p53 levels may also impact on the
pathology of tumours. When the phenotypes of mice expres-
sing varying amounts of p53R172H in the same genetic
background were compared, it was evident that mutant p53
expression levels influenced the type of tumour.40 Low and
intermediate levels were associated with predominately
sarcomas and some lymphomas and carcinomas. The
highest expression was associated with mostly lymphoma,
half the frequency of sarcoma and no carcinoma.40
We have shown that loss of S100A2 leads to an increase in
sensitivity to the HSP90 inhibitor 17-AAG. This may therefore
represent a novel therapeutic strategy for targeting S100A2-
deficient tumours, which according to our studies would
include BRCA1-deficient breast cancers. A recent study has
shown that BRCA1-deficient cells are acutely sensitive to
17-AAG owing to impaired G2/M checkpoint activation and
thus mitotic catastrophe.41 They also show that BRCA1 is a
client protein of HSP90 and treatment with 17-AAG results in
ubiquitination-dependent degradation of BRCA1, resulting in
decreased DNA damage repair.41 17-AAG may therefore
allow induction of a ‘BRCAness’ state, which increases
sensitivity to common DNA-damaging therapeutics such as
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ionising radiation as well as PARP inhibitors. Our work further
highlights the interplay between BRCA1 and HSP90 inhibi-
tion. We propose that BRCA1-deficient breast tumours, where
abrogation of p53 function through mutation, appear to be a
prerequisite for BRCA1-defective cancers to progress, would
be extremely sensitive to 17-AAG treatment owing to the loss
of S100A2 expression and thus increased HSP90-dependent
stabilisation of mutant p53. In addition, 17-AAG may further
downregulate BRCA1 levels, and thus S100A2, resulting in
greater drug sensitivity.
HSP90 is an attractive drug target owing to the fact that most
inhibitors display selectivity for tumour over normal cells.
Currently, there are 17 different HSP90 inhibitors in clinical
trials in a variety of different cancer types.42 However, no HSP90
inhibitor has been FDA approved to date. Although phase I
clinical trials of geldanamycin derivatives showed promising
results, monotherapy showed little activity in phase II. This may
be due to the suboptimal doses of the drugs used to avoid
toxicity.43 However, HSP90 inhibitors have shown promising
results when used in combination with other agents such as
herceptin for the treatment of Her2positive breast cancers.44
As with most modern targeted therapies, personalising treat-
ments to match the patients’ genetic profile or particular tumour
types may increase the effectiveness of HSP90 inhibition.
S100A2 may therefore represent a novel biomarker of response
to HSP90 inhibitors and BRCA1-deficient tumours may benefit
from the combination of HSP90 inhibition with DNA-damaging
agents such as PARP inhibitors. Alternatively, other agents,
which have been shown to interfere with HSP90 binding to
client proteins, such as histone deacteylase inhibitors,45 may
also prove useful in treating BRCA1-deficient cancers.
Materials and Methods
Cell lines. All cell lines were purchased from ATCC (in partnership with LGC
Standards, Middlesex, UK). Cell lines were characterised by isoenzyme/
cytochrome c oxidase I assay and short tandem repeat analysis by the cell
bank. Full details of the HCC-EV/BR, MDA468-EV/BR and MCF7 cell lines
are provided in Mullan et al.46 and Tkocz et al.47 HCC1937 and MDA468-EV
and -S100A2 cells were generated by stable retrovirus transfection of the cells with
(i) pBabe EV or pBabe S100A2 constructs, respectively. Infected cells were
selected in the presence of 1 mg/ml puromycin. All other cell lines were maintained
as described previously.48
Cloning of S100A2 and its promoter. Flag-tagged S100A2 was PCR
amplified and cloned into pBabe-puro EV. Primers are listed in Supplementary
Materials and Methods. S100A2 regulatory regions were cloned into pGL3 basic
using primers described elsewhere.14
Short interfering RNA. Transfections were carried out using Oligofectamine
reagent (Invitrogen, Paisley, UK), as outlined in the manufacturer’s instructions.
SiRNA oligonucleotide were obtained from Dharmacon (Leicestershire, UK)
and used at a final concentration of 100 nM. siRNA sequences are S100A2 no. 2,
50-ACAAGTTCAAGCTGAGTAA-30; S100A2 no. 3, 50-GCCAAGAGGGCGACAA
GTT-30. All other siRNA has been described previously.5
Western blot analysis. Protein lysates were extracted in EDTA lysis buffer
(0.25 M NaCl, 0.1% IEPGAL, 0.25 M HEPES, 5 mM EDTA, 0.5 mM DTT),
separated on a SDS-PAGE gel and then transferred to a PVDF membrane
followed by immunoblotting.
Immunoprecipitation. Total, native and denatured p53 was immunopreci-
pitated from cells using DO-1 (Santa Cruz Biotechnology, Dallas, TX, USA),
PAb1620 and PAb240, respectively. Briefly 750mg of proteins were incubated with
2mg antibody coupled to Protein G Dynabeads (Invitrogen) overnight. Samples
were washed five times in IP buffer (0.5% NP-40, 50 mM HEPES (pH 7.5),
100 mM NaCl, 1 mM DTT) and resolved by western blot analysis. Densitometry
was carried out using ImageJ.49
RNA extraction, reverse transcription and real-time quantitative
PCR. RNA was extracted using RNA STAT-60 Total RNA extraction Reagent
(Tel-Test Inc., Friendswood, TX, USA), reverse transcribed using the Transcriptor
First Strand cDNA Synthesis kit (Roche, Burgess Hill, UK) and real-time
quantitative PCR analysis performed on the Light Cycler 480 system (Roche)
using SYBR Green (Roche) according to the manufacturer’s instructions. Primers
used are: S100A2 – F, 50-GCTCTCCTTCCTGGGTCTGT-30 and R, 50-TGCTCCA
GAGAACTGCACAT-30; p53 – F, 50-TCCGAGTGGAAGGAAATTTGC-30 and R,
50-GATGGTGGTACAGTCAGAGCC-30; cloning full-length Flag-tagged S100A2 – F,
50-GCCATGGACTACAAGGACGACGATGACAAGATGTGCAGTTCTCTGGAG-30
and R, 50-GCTTCAGGGTCGGTCTG-30. All other primers have been described
previously.5,6,39,50
Luciferase assays. Cells were co-transfected with the relevant luciferase
constructs and Renilla using GeneJuice (Novagen, Middlesex, UK) according to
the manufacturer’s instructions. After 24 h, cells were lysed with Passive Lysis
Buffer (Promega, Madison, WI, USA) and luciferase and Renilla activities were
assessed by luminescence using D-luciferin and coelenterazine as substrates,
respectively. Site-directed mutagenesis was carried out using KOD polymerase
(Novagen) according to the manufacturer’s instructions.
ChIP assays. ChIP assays were performed as described previously.51 PCR
was performed on extracted DNA using Taq DNA polymerase (Roche) according
to the manufacturer’s instructions. Primers used are as in Kirschner et al.15
HSP90 inhibition. For dose–response curves, cells treated with a range of
concentrations of 17-AAG (log 10 12 log 10 6 M) for 72 h before cell viability
was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (Sigma, Dorset, UK). For other studies, cells were incubated with 4mM
(MDA-MB-468) or 2 mM (HCC1937) 17-AAG for 16 h.
S100A2 expression in breast tumours. Publically available data sets52–54
with BRCA1 mutation/methylation status were analysed using Oncomine
(www.oncomine.org) for S100A2 expression.
Correlation of S100A2 expression and 17-DMAG IC50 values.
17-DMAG IC50 values for a range of cell lines were extrapolated from Lehmann
et al.24 Using the publically available data sets used within this paper (GSE10890
and E-TABM-157), microarray data from cell lines was analysed for S100A2
expression using R (www.r-project.org). Samples were background-corrected,
normalised and transformed using the Affy package, justRMA (www.bioconductor.org).
The probe set for S100A2 was identified and the relevant expression levels
determined. Correlation between S100A2 and 17-DMAG IC50 values was assessed
by Spearman’s correlation in Prism.
BrdU incorporation. Cells were treated with 10mM BrdU for 20 min minutes
before fixing with 4% paraformaldehyde. Cells were then stained with the FITC
mouse anti-BrdU set (BD Pharmingen, Oxford, UK) according to the
manufacturer’s instructions. BrdU-positive cells were then counted and expressed
as a percentage of total cells.
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